Rate My Professor Jhong Haw

Dr Tatt Jhong Haw is a Postdoctoral Research Fellow in the School of Medicine and Public Health at the University of Newcastle, affiliated with the Hunter Medical Research Institute. He earned a Doctor of Philosophy from the University of Newcastle and a Bachelor of Science with Honours in Biomedical Science from the International Medical University in Malaysia. His research specializations encompass cardio-oncology, cardio-respiratory health, airborne particulate pollution, bushfire smoke exposure, cardioprotection, cardiovascular disease, environmental determinants of health, and applications of human induced-pluripotent stem cells. As a key member of the Newcastle Cardio-Oncology Research Program—the only program in Australia certified as an International Cardio-Oncology Society Centre of Excellence—Haw investigates mechanisms of anti-cancer therapy-induced cardiotoxicity using animal models, in vitro cultures, and human stem cell-derived cardiomyocytes. He has managed preclinical studies with industry partners including Race Oncology, Allakos, PharmAkea, AusBio, Pharmaxis, and Genentech, completing over 12 projects on therapeutics for emphysema, COPD, and influenza-related conditions.

Haw's career at the University of Newcastle spans from Research Associate (2016-2020) and Research Assistant (2020) to Postdoctoral Researcher (2021-2022) and his current role. With an H-index of 18 and over 1,600 citations across more than 50 publications, his contributions include pioneering models for landscape fire smoke exposure and identifying molecular pathways in smoke-induced lung damage. Notable publications are 'Bushfire Smoke Induces Cardiac Dysfunction Via Oxidative Stress and Mitochondria Impairment' (2023, Heart, Lung and Circulation), 'The clinically active PARP inhibitor olaparib ameliorates doxorubicin-induced cardiotoxicity in both in vitro and in vivo model' (2023, European Heart Journal), 'TLR7 promotes smoke-induced experimental lung damage through the activity of mast cell tryptase' (2023, Nature Communications), 'Anti-cancer agent Olaparib ameliorates doxorubicin-induced cardiotoxicity in vitro and in vivo' (2025, Journal of Molecular and Cellular Cardiology), and 'Landscape fire smoke airway exposure impairs respiratory and cardiac function and worsens experimental asthma' (2024, Journal of Allergy and Clinical Immunology). His research has generated a patent (PCT:AU2024903478), informed a Phase 2b clinical trial, and secured over $1.1 million in grants, including a Heart Foundation Vanguard Grant. Awards include the 2025 Basic Cardiovascular Science Award at the Cardiac Society of Australia and New Zealand, 2023 NSW Cardiovascular Research Network Professional Development Award, and multiple travel grants from the School of Medicine and Public Health. Haw has supervised five completed and one current research student, serves as a member of the Australian Cardiovascular Alliance, and engages in community partnerships such as with the Swansea Rural Fire Brigade.